Experimental combo for Hard-to-Treat cancers shows early promise but study halted
NCT ID NCT05580770
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. The study was terminated early, so results are limited, but the data may help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirdametinib and brimarafenib (BGB-3245) combination
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This was a very early (Phase 1/2a) study with only 23 participants, and it was terminated early. The combination may cause side effects and may not shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Calvary Mater Newcastle
Waratah, 2298, Australia
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut, 06520, United States